Immune Protein Fends Off Exotic Virus
A study published online on Feb. 1 in the Journal of Experimental Medicine shows that antiviral proteins called type I interferons (IFNs) are needed to fend off infection with an exotic mosquito-borne virus called Chikungunya virus. This pathogen, which causes high fevers and severe joint pain, triggered a recent epidemic in Southeast Asia, infecting more than 30 percent of the population in some areas.
A team led by Marc Lecuit and Matthew Albert at the Pasteur Institute in Paris found that individuals infected with Chikungunya virus had increased levels of type I IFNs in their blood. But the source of the virus-fighting IFN proteins came as a surprise. Viruses related to Chikungunya trigger type I IFN production mostly from immune cells. But during Chikungunya infection, immune cells neither produced nor responded to type I IFNs. Rather non-immune cells called fibroblasts—the main target of virus infection—provided the essential type I IFN.
This unique feature should be taken into consideration in future efforts to develop therapeutic strategies for controlling Chikungunya virus infection.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.
Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski
June 26th 2025In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.
